Literature DB >> 20660805

Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).

Gregg C Fonarow1, Nancy M Albert, Anne B Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J Thomas Heywood, Mark L McBride, Patches Johnson Inge, Mandeep R Mehra, Christopher M O'Connor, Dwight Reynolds, Mary Norine Walsh, Clyde W Yancy.   

Abstract

BACKGROUND: A treatment gap exists between heart failure (HF) guidelines and the clinical care of patients. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) prospectively tested a multidimensional practice-specific performance improvement intervention on the use of guideline-recommended therapies for HF in outpatient cardiology practices. METHODS AND
RESULTS: Performance data were collected in a random sample of HF patients from 167 US outpatient cardiology practices at baseline, longitudinally after intervention at 12 and 24 months, and in single-point-in-time patient cohorts at 6 and 18 months. Participants included 34 810 patients with reduced left ventricular ejection fraction (< or =35%) and chronic HF or previous myocardial infarction. To quantify guideline adherence, 7 quality measures were assessed. Interventions included clinical decision support tools, structured improvement strategies, and chart audits with feedback. The performance improvement intervention resulted in significant improvements in 5 of 7 quality measures at the 24-month assessment compared with baseline: beta-blocker (92.2% versus 86.0%, +6.2%), aldosterone antagonist (60.3% versus 34.5%, +25.1%), cardiac resynchronization therapy (66.3% versus 37.2%, +29.9%), implantable cardioverter-defibrillator (77.5% versus 50.1%, +27.4%), and HF education (72.1% versus 59.5%, +12.6%) (each P<0.001). There were no statistically significant improvements in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use or anticoagulation for atrial fibrillation. Sensitivity analyses at the patient level and limited to patients with both baseline and 24-month quality measure data yielded similar results. Improvements in the single-point-in-time cohorts were smaller, and there were no concurrent control practices.
CONCLUSIONS: The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting, a defined and scalable practice-specific performance improvement intervention, was associated with substantial improvements in the use of guideline-recommended therapies in eligible patients with HF in outpatient cardiology practices. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00303979.

Entities:  

Mesh:

Year:  2010        PMID: 20660805     DOI: 10.1161/CIRCULATIONAHA.109.934471

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  109 in total

1.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008.

Authors:  Jersey Chen; Sharon-Lise T Normand; Yun Wang; Harlan M Krumholz
Journal:  JAMA       Date:  2011-10-19       Impact factor: 56.272

2.  Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?

Authors:  Sana M Al-Khatib; Anne S Hellkamp; Adrian F Hernandez; Gregg C Fonarow; Kevin L Thomas; Hussein R Al-Khalidi; Paul A Heidenreich; Stephen Hammill; Clyde Yancy; Eric D Peterson
Journal:  Circulation       Date:  2012-01-27       Impact factor: 29.690

3.  Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Authors:  Paul L Hess; Sana M Al-Khatib; Joo Y Han; Rex Edwards; Gust H Bardy; J Thomas Bigger; Alfred Buxton; Riccardo Cappato; Paul Dorian; Al Hallstrom; Alan H Kadish; Peter J Kudenchuk; Kerry L Lee; Daniel B Mark; Arthur J Moss; Richard Steinman; Lurdes Y T Inoue; Gillian Sanders
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-02-10

4.  Trends in prevalence of comorbidities in heart failure clinical trials.

Authors:  Muhammad Shahzeb Khan; Ayman Samman Tahhan; Muthiah Vaduganathan; Stephen J Greene; Alaaeddin Alrohaibani; Stefan D Anker; Orly Vardeny; Gregg C Fonarow; Javed Butler
Journal:  Eur J Heart Fail       Date:  2020-04-15       Impact factor: 15.534

5.  Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.

Authors:  Larry A Allen; Susan M Shetterly; Pamela N Peterson; Jerry H Gurwitz; David H Smith; David W Brand; Diane L Fairclough; John S Rumsfeld; Frederick A Masoudi; David J Magid
Journal:  Circ Heart Fail       Date:  2013-11-26       Impact factor: 8.790

6.  Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.

Authors:  Catherine N Marti; Gregg C Fonarow; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

7.  Performance of Consultative Palliative Care Model in Achieving Quality Metrics in the ICU.

Authors:  Nicholas G Wysham; Michael J Hochman; Steven P Wolf; Christopher E Cox; Arif H Kamal
Journal:  J Pain Symptom Manage       Date:  2016-09-30       Impact factor: 3.612

8.  Failure to reassess ejection fraction after acute myocardial infarction in potential implantable cardioverter/defibrillator candidates: insights from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status (TRIUMPH) registry.

Authors:  Amy Leigh Miller; Kensey Gosch; Stacie L Daugherty; Saif Rathore; Pamela N Peterson; Eric D Peterson; P Michael Ho; Paul S Chan; David E Lanfear; John A Spertus; Tracy Y Wang
Journal:  Am Heart J       Date:  2013-09-05       Impact factor: 4.749

9.  Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation.

Authors:  Nancy Luo; Haolin Xu; Hani Jneid; Gregg C Fonarow; Renato D Lopes; Jonathan P Piccini; Anne B Curtis; Andrea M Russo; William R Lewis; Roland A Matsouaka; Christopher B Granger; Robert J Mentz; Sana M Al-Khatib
Journal:  Circ Heart Fail       Date:  2018-10       Impact factor: 8.790

10.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.